Roche to Pay Up to $548 Million for ‘Superbug’ Antibiotic

Roche Holding AG agreed to pay as much as 500 million Swiss francs ($548 million) for the rights to an experimental antibiotic to target a drug-resistant “superbug” that is a leading cause of fatal bacterial infections in hospitals.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.